Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CAROL H WYSHAM

Allopathic & Osteopathic Physicians Internal Medicine Endocrinology, Diabetes & Metabolism

NPI
1457344541
CMS profile
338808
Location
SPOKANE, WA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$125,595.81

148 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
Abbott Laboratories $48,485.50 90
Novo Nordisk Inc $46,859.32 32
Eli Lilly and Company $21,928.32 14
Lilly USA, LLC $8,050.32 10
Medtronic, Inc. $239.52 1
CeQur Corporation $32.83 1

Page 3 of 3; records 101–148 of 148 matching records. This page contains 48 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CAROL H WYSHAM

NPI 1457344541 · CMS profile ID 338808

Allopathic & Osteopathic Physicians / Internal Medicine / Endocrinology, Diabetes & Metabolism

SPOKANE, WA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–148 of 148 matching records. This page contains 48 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1457344541?year=2025&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CAROL H WYSHAM, NPI 1457344541, CMS profile ID 338808. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–148 of 148 matching records. This page contains 48 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1457344541?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). CAROL H WYSHAM, NPI 1457344541, CMS profile ID 338808. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–148 of 148 matching records. This page contains 48 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1457344541?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
CAROL H WYSHAM, NPI 1457344541, CMS profile ID 338808, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–148 of 148 matching records. This page contains 48 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1457344541?year=2025&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

148 matching records · $125,595.81 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 148 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–148 of 148.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Abbott Laboratories $106.5205/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1240975900 CMS
Abbott Laboratories $111.7205/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1240975902 CMS
Abbott Laboratories $487.3705/23/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1241102435 CMS
Abbott Laboratories $25.0005/23/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1241102437 CMS
Abbott Laboratories $299.7905/23/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1241102439 CMS
Abbott Laboratories $9.0205/23/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1241104813 CMS
Eli Lilly and Company $4,950.0005/22/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1186484535 CMS
Eli Lilly and Company $1,925.0005/22/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1186538905 CMS
Novo Nordisk Inc $1,362.5005/07/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1189007175 CMS
Eli Lilly and Company $181.0005/02/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1186472285 CMS
Eli Lilly and Company $60.0005/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186472287 CMS
Eli Lilly and Company $684.9605/02/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1186538903 CMS
Eli Lilly and Company $55.0005/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186538907 CMS
Eli Lilly and Company $23.6805/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186541095 CMS
Eli Lilly and Company $23.6805/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186541097 CMS
Eli Lilly and Company $170.0005/02/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1186541099 CMS
Eli Lilly and Company $90.0005/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186548228 CMS
Eli Lilly and Company $175.0005/02/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1186551030 CMS
Eli Lilly and Company $140.0005/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186551032 CMS
Abbott Laboratories $6,300.0004/30/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1240565529 CMS
Novo Nordisk Inc $2,452.5004/29/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1188388695 CMS
Novo Nordisk Inc $125.0004/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1189088390 CMS
Novo Nordisk Inc $1,090.0004/11/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1188357872 CMS
Novo Nordisk Inc $125.0004/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1188470917 CMS
Novo Nordisk Inc $3,542.5004/08/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1189010332 CMS
Novo Nordisk Inc $1,090.0004/03/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1189111828 CMS
Abbott Laboratories $139.6703/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1240984348 CMS
Abbott Laboratories $49.3603/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1240984482 CMS
Abbott Laboratories $70.7103/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1240984616 CMS
Abbott Laboratories $51.5503/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1240984750 CMS
Abbott Laboratories $78.7103/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1240983946 CMS
Abbott Laboratories $53.2803/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1240984080 CMS
Abbott Laboratories $139.6703/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1240984214 CMS
Abbott Laboratories $643.9703/28/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1241102810 CMS
Abbott Laboratories $200.1403/28/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1241102942 CMS
Novo Nordisk Inc $1,090.0003/26/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1189052784 CMS
Novo Nordisk Inc $399.3803/08/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1188869577 CMS
Novo Nordisk Inc $730.7703/08/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1188891260 CMS
Novo Nordisk Inc $7,698.1303/08/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1188977176 CMS
Novo Nordisk Inc $298.3003/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1189108106 CMS
Novo Nordisk Inc $120.6703/08/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1189110330 CMS
Lilly USA, LLC $68.9603/04/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1186472289 CMS
Lilly USA, LLC $34.0803/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186538913 CMS
Lilly USA, LLC $56.3403/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186541103 CMS
Lilly USA, LLC $33.4803/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186545505 CMS
Lilly USA, LLC $6.5003/04/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1186548232 CMS
Lilly USA, LLC $4,400.0002/28/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1186538911 CMS
Lilly USA, LLC $365.8402/21/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1186545503 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $283,374.91 206
PY2020 $4,679.20 3
PY2021 $1,137.65 11
PY2022 $1,769.67 10
PY2023 $31,343.37 41
PY2024 $63,949.81 88
PY2025 $125,595.81 148

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $136,091.07 29
PY2024 Recipient $10,274.00 1
PY2024 Principal investigator $97,176.14 43
PY2023 Recipient $1,502.53 1
PY2023 Principal investigator $110,732.17 66
PY2022 Recipient $15,150.00 1
PY2022 Principal investigator $105,554.65 65
PY2021 Recipient $865.30 1
PY2021 Principal investigator $227,126.94 194
PY2020 Recipient $164.65 1
PY2020 Principal investigator $301,804.24 186
PY2019 Recipient $4,088.11 8
PY2019 Principal investigator $83,048.18 72

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

29 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $5,612.00 12/31/2025 Covered Recipient Teaching Hospital
GOOD SAMARITAN HOSPITAL
A Phase 2/3 multicenter, double blinded, randomized, dose-conversion, active control study examining the efficacy and safety of Armour Thyroid compared to synthetic T4 for the treatment of adults with primary hypothyroidism No dispute reported 06/30/2026 1202411853
Principal investigator 1 ABBVIE INC. $500.00 12/23/2025 Covered Recipient Teaching Hospital
GOOD SAMARITAN HOSPITAL
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202411849
Principal investigator 1 ABBVIE INC. $6,317.88 11/05/2025 Covered Recipient Teaching Hospital
GOOD SAMARITAN HOSPITAL
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202411836
Principal investigator 1 Novo Nordisk AS $807.75 10/29/2025 Covered Recipient Teaching Hospital
Deaconess Medical Center
NN9535-4352 No dispute reported 06/30/2026 1213714748
Principal investigator 1 Novo Nordisk AS $644.62 10/29/2025 Covered Recipient Teaching Hospital
Deaconess Medical Center
NN9535-4352 No dispute reported 06/30/2026 1213850252
Principal investigator 1 ABBVIE INC. $7,972.32 10/09/2025 Covered Recipient Teaching Hospital
GOOD SAMARITAN HOSPITAL
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202411828
Principal investigator 1 ABBVIE INC. $1,500.00 09/09/2025 Covered Recipient Teaching Hospital
GOOD SAMARITAN HOSPITAL
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202411820
Principal investigator 1 ABBVIE INC. $9,176.60 09/04/2025 Covered Recipient Teaching Hospital
GOOD SAMARITAN HOSPITAL
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202411816
Principal investigator 1 Novo Nordisk AS $1,500.00 08/22/2025 Covered Recipient Teaching Hospital
Deaconess Medical Center
NN9535-4352 No dispute reported 06/30/2026 1213788985
Principal investigator 1 ABBVIE INC. $4,567.56 08/06/2025 Covered Recipient Teaching Hospital
GOOD SAMARITAN HOSPITAL
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202411798
Principal investigator 1 Novo Nordisk AS $386.44 07/18/2025 Covered Recipient Teaching Hospital
Deaconess Medical Center
NN9535-4352 No dispute reported 06/30/2026 1213717128
Principal investigator 1 ABBVIE INC. $4,802.16 07/02/2025 Covered Recipient Teaching Hospital
GOOD SAMARITAN HOSPITAL
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202411794
Principal investigator 1 ABBVIE INC. $3,340.84 06/03/2025 Covered Recipient Teaching Hospital
GOOD SAMARITAN HOSPITAL
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202411783
Principal investigator 1 Novo Nordisk AS $1,200.00 05/21/2025 Covered Recipient Teaching Hospital
Deaconess Medical Center
NN9535-4352 No dispute reported 06/30/2026 1213775396
Principal investigator 1 ABBVIE INC. $7,662.92 05/07/2025 Covered Recipient Teaching Hospital
GOOD SAMARITAN HOSPITAL
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202411768
Principal investigator 1 ABBVIE INC. $6,940.00 05/02/2025 Covered Recipient Teaching Hospital
GOOD SAMARITAN HOSPITAL
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202411764
Principal investigator 1 Novo Nordisk AS $838.12 04/21/2025 Covered Recipient Teaching Hospital
Deaconess Medical Center
NN9535-4352 No dispute reported 06/30/2026 1213734553
Principal investigator 1 Novo Nordisk AS $937.12 04/21/2025 Covered Recipient Teaching Hospital
Deaconess Medical Center
NN9535-4352 No dispute reported 06/30/2026 1213795583
Principal investigator 1 ABBVIE INC. $9,677.76 04/03/2025 Covered Recipient Teaching Hospital
GOOD SAMARITAN HOSPITAL
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202411761
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $68.00 03/19/2025 Non-covered Recipient Entity
Multicare Health System
BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in participants with chronic kidney disease and type 2 diabetes No dispute reported 06/30/2026 1225405084
Principal investigator 1 ABBVIE INC. $3,635.96 03/07/2025 Covered Recipient Teaching Hospital
GOOD SAMARITAN HOSPITAL
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202411750
Principal investigator 1 Eli Lilly and Company $329.40 02/25/2025 Covered Recipient Teaching Hospital
DEACONESS MEDICAL CENTER
THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) No dispute reported 06/30/2026 1187873953
Principal investigator 1 Novo Nordisk AS $386.44 02/21/2025 Covered Recipient Teaching Hospital
Deaconess Medical Center
NN9535-4352 No dispute reported 06/30/2026 1213713713
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $68.00 02/07/2025 Non-covered Recipient Entity
Multicare Health System
BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in participants with chronic kidney disease and type 2 diabetes No dispute reported 06/30/2026 1225404365
Principal investigator 1 ABBVIE INC. $6,385.88 02/06/2025 Covered Recipient Teaching Hospital
GOOD SAMARITAN HOSPITAL
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202411743
Principal investigator 1 Eli Lilly and Company $249.86 01/31/2025 Covered Recipient Teaching Hospital
DEACONESS MEDICAL CENTER
A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) No dispute reported 06/30/2026 1187873955
Principal investigator 1 Novo Nordisk AS $386.44 01/31/2025 Covered Recipient Teaching Hospital
Deaconess Medical Center
NN9535-4352 No dispute reported 06/30/2026 1213718344
Principal investigator 1 Eli Lilly and Company $27,470.00 01/21/2025 Covered Recipient Teaching Hospital
DEACONESS MEDICAL CENTER
THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) No dispute reported 06/30/2026 1187873951
Principal investigator 1 Eli Lilly and Company $22,727.00 01/07/2025 Covered Recipient Teaching Hospital
DEACONESS MEDICAL CENTER
A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) No dispute reported 06/30/2026 1187873075